Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Corifollitropin Alfa Market by Type (Industrial Grade, Pharmaceutical Grade, Others) and by End User (Hospitals, Laboratories): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03633

Pages: NA

Charts: NA

Tables: NA

Corifollitropin alfa is a hybrid follicle-stimulating hormone (FSH) molecule, which is used to treat infertility. This molecule when injected results in the development of a high number of metaphase II oocytes in women.

The major factor that contributes to the growth of the corifollitropin alfa market is the high incidence of infertility in young people due to various reasons such as polycystic ovary syndrome and blockage in fallopian tube. Moreover, rapid rise in the number of fertility clinics, growing awareness about infertility treating hormones among population, and technological advancements in the healthcare sector enhance the market growth. However, high-cost infertility treatments and stringent regulatory issues may hinder the market growth. The improvement in corifollitropin alfa efficacy for in vitro fertilsation by introducing novel techniques will further boost the market growth.

The corifollitropin alfa market is segmented on the basis of types, end user, and region. Based on type the market is segmented into industrial grade, pharmaceutical grade, and others. On the basis of end user, the market is classified into hospitals and laboratories. By geography, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Merck & Co., Inc., Schering-Plough Corporation, Ferring B.V., and many more.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the market which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale has been provided.
  • Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the global market.

 Key Market Segments

  • By Type
    • Industrial Grade
    • Pharmaceutical Grade
    • Others
  • By End User
    • Hospitals
    • Laboratories
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Merck & Co., Inc.
  • Ferring B.V.
  • Schering-Plough Corporation

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: CORIFOLLITROPIN ALFA MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Industrial Grade

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Pharmaceutical Grade

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: CORIFOLLITROPIN ALFA MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Laboratories

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: CORIFOLLITROPIN ALFA MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Corifollitropin Alfa Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Corifollitropin Alfa Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Corifollitropin Alfa Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Corifollitropin Alfa Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Corifollitropin Alfa Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Corifollitropin Alfa Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Corifollitropin Alfa Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Corifollitropin Alfa Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Corifollitropin Alfa Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Corifollitropin Alfa Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Corifollitropin Alfa Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Corifollitropin Alfa Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Corifollitropin Alfa Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Corifollitropin Alfa Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Corifollitropin Alfa Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Corifollitropin Alfa Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Corifollitropin Alfa Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Corifollitropin Alfa Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Corifollitropin Alfa Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Corifollitropin Alfa Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Corifollitropin Alfa Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Corifollitropin Alfa Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Corifollitropin Alfa Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Corifollitropin Alfa Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Corifollitropin Alfa Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Merck And Co., Inc.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Schering-Plough Corporation

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Ferring B.V.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CORIFOLLITROPIN ALFA MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL CORIFOLLITROPIN ALFA MARKET FOR INDUSTRIAL GRADE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL CORIFOLLITROPIN ALFA MARKET FOR PHARMACEUTICAL GRADE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL CORIFOLLITROPIN ALFA MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL CORIFOLLITROPIN ALFA MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL CORIFOLLITROPIN ALFA MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL CORIFOLLITROPIN ALFA MARKET FOR LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL CORIFOLLITROPIN ALFA MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA CORIFOLLITROPIN ALFA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 12. U.S. CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 13. U.S. CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 14. CANADA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 15. CANADA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 16. MEXICO CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 18. EUROPE CORIFOLLITROPIN ALFA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. FRANCE CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. GERMANY CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. ITALY CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. ITALY CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 27. SPAIN CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. UK CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. UK CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 31. RUSSIA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. REST OF EUROPE CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. ASIA-PACIFIC CORIFOLLITROPIN ALFA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. CHINA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 39. CHINA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. JAPAN CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. INDIA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. INDIA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. SOUTH KOREA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 46. AUSTRALIA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. THAILAND CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. MALAYSIA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 52. INDONESIA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 56. LAMEA CORIFOLLITROPIN ALFA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. BRAZIL CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. SOUTH AFRICA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. SAUDI ARABIA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. UAE CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. UAE CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. ARGENTINA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. REST OF LAMEA CORIFOLLITROPIN ALFA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA CORIFOLLITROPIN ALFA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 71. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 72. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 73. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 74. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 75. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. SCHERING-PLOUGH CORPORATION: KEY EXECUTIVES
  • TABLE 77. SCHERING-PLOUGH CORPORATION: COMPANY SNAPSHOT
  • TABLE 78. SCHERING-PLOUGH CORPORATION: OPERATING SEGMENTS
  • TABLE 79. SCHERING-PLOUGH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 80. SCHERING-PLOUGH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. FERRING B.V.: KEY EXECUTIVES
  • TABLE 82. FERRING B.V.: COMPANY SNAPSHOT
  • TABLE 83. FERRING B.V.: OPERATING SEGMENTS
  • TABLE 84. FERRING B.V.: PRODUCT PORTFOLIO
  • TABLE 85. FERRING B.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CORIFOLLITROPIN ALFA MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CORIFOLLITROPIN ALFA MARKET
  • FIGURE 3. SEGMENTATION CORIFOLLITROPIN ALFA MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CORIFOLLITROPIN ALFA MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCORIFOLLITROPIN ALFA MARKET
  • FIGURE 11. CORIFOLLITROPIN ALFA MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. CORIFOLLITROPIN ALFA MARKET FOR INDUSTRIAL GRADE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. CORIFOLLITROPIN ALFA MARKET FOR PHARMACEUTICAL GRADE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. CORIFOLLITROPIN ALFA MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. CORIFOLLITROPIN ALFA MARKET SEGMENTATION, BY BY END USER
  • FIGURE 16. CORIFOLLITROPIN ALFA MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. CORIFOLLITROPIN ALFA MARKET FOR LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: CORIFOLLITROPIN ALFA MARKET
  • FIGURE 24. TOP PLAYER POSITIONING, 2024
  • FIGURE 25. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 26. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 27. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 28. SCHERING-PLOUGH CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. SCHERING-PLOUGH CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. SCHERING-PLOUGH CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. FERRING B.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. FERRING B.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. FERRING B.V.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Corifollitropin Alfa Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved